Background. The sensitivity of blood cultures for diagnosing invasive candidiasis (IC) is poor. Methods. We performed a validated Candida real-time polymerase chain reaction (PCR) and the Fungitell 1,3-b-D-glucan (BDG) assay on blood samples collected from prospectively identified patients with IC (n 5 55) and hospitalized controls (n 5 73). Patients with IC had candidemia (n 5 17), deep-seated candidiasis (n 5 33), or both (n 5 5). Controls had mucosal candidiasis (n 5 5), Candida colonization (n 5 48), or no known Candida colonization (n 5 20).
Invasive candidiasis (IC) carries significant morbidity and mortality. In part, poor outcomes stem from delayed or missed diagnoses using blood and sterile-site cultures, the current gold standard tests. Indeed, blood cultures are negative for Candida species in approximately 50% of autopsy-proven cases of disseminated candidiasis [1] [2] [3] ; moreover, they often become positive late in the disease course. Sterile-site cultures are further limited by the need for invasive sampling. As such, there is much interest in developing rapid and more sensitive diagnostic assays. Two approaches that have gained particular attention are detection of 1,3-b-D-glucan (BDG), a major constituent of fungal cell walls, and polymerase chain reaction (PCR) amplification of Candida DNA. Despite their promise, neither test is a standard of clinical practice. The sensitivity of a commercial assay for BDG quantitation (Fungitell, Associates of Cape Cod) has varied from 64% to 100% [4] [5] [6] , and Candida PCR methods are not validated.
In this study, we compared the performance of a Candida real-time PCR assay, which was validated at Viracor-IBT Laboratories according to relevant clinical laboratory guidelines [7] , with the Fungitell BDG assay and blood cultures for diagnosing IC. We included samples from a wide range of patients with IC, including those with candidemia, catheter-related candidemia, and deep-seated candidiasis with or without positive blood cultures. To rigorously evaluate the specificity of the assays, our control group was comprised largely of patients with mucosal candidiasis or who were colonized with Candida at nonsterile sites.
METHODS
We conducted a prospective study of patients at the University of Pittsburgh Medical Center between April 2009 and April 2011. Blood was collected from consenting controls and patients with IC, and serum or plasma samples were stored at 280°C. Whole blood testing was performed on fresh samples. The study was approved by our institutional review board.
Definitions
Invasive candidiasis included candidemia and deep-seated candidiasis [8] , which were defined as the recovery of Candida species from blood or a sterile site, respectively. Controls were defined as hospitalized patients who did not have clinical or microbiological evidence of IC. Patients with mucosal candidiasis or colonized with Candida were also included as controls. Colonization was defined as the recovery of Candida species from nonsterile sites in patients without symptoms or signs of a systemic disease that were attributable to candidiasis. Blood and deep-seated cultures were considered to be concurrent if performed within 5 days of each other. Positive, indeterminate, and negative BDG results were defined as $80, 60 to ,80, and ,60 pmol/mL, respectively. Candida were speciated using standard mycological methods of carbohydrate assimilation using the API 20C kit (bioMérieux, Hazelwood, Missouri) and morphology on cornmeal agar. CHROMagar (BD Diagnostics) or other differential media to speciate Candida were not used.
BDG Testing and Real-time PCR
Frozen plasma and serum samples were shipped overnight, on dry ice, in batch to Viracor-IBT Laboratories for BDG and PCR testing. Whole blood samples were sent unfrozen on ice and processed within 24 hours of venipuncture. The Fungitell BDG assay was performed according to the manufacturer's instructions. For PCR, DNA from whole blood, plasma, and serum was extracted using the DNeasy Blood and Tissue kit (Qiagen, Germantown, Maryland). After adding an internal control target (engineered bacteriophage), 500 lL of specimen was manually extracted using a 35-lL elution volume. An internal control cutoff quantification cycle of 37 was required for reporting a negative result. A positive extraction control, negative extraction control, and no template control were included in every PCR run. For the design of species-specific TaqMan real-time assays, alignments of available ITS1 and/or ITS2 sequences for 4 Candida species (Candida albicans, Candida glabrata, Candida krusei, and Candida tropicalis) and 1 species complex (Candida parapsilosis complex) were created using Geneious software (Biomatters, Auckland, New Zealand.). Primers were designed to detect 2 species pairs (C. albicans/C. tropicalis and C. glabrata/C. krusei), and C. parapsilosis. The ABI 7500 Fast Instrument (Applied Biosystems, Carlsbad, California) was used with a final reaction volume of 30 lL utilizing 10 lL of template DNA. The amplification efficiencies, determined using 10-fold dilutions of plasmid standards ranging from 10 to 1 3 10 8 copies per reaction, were 99.3%, 96.5%, 102.5%, 97.4%, and 98.7% for C. albicans, C. glabrata, C. krusei, C. parapsilosis complex, and C. tropicalis, respectively. The analytical specificities for the Candida PCR assays tested with various targeted Candida species, nontargeted fungi, and bacteria and were 100% (7/7), 95% (37/39) and 100% (28/28), respectively ( Table 1 ). The analytical sensitivity using targeted Candida species was 100% (7/7).
Statistical Analysis
Sensitivity and specificity were calculated for blood culture, BDG, and PCR. The McNemar v 2 test was used to compare sensitivity and specificity between assays [9] . Univariate analysis of contingency data was done by v 2 or Fisher exact test.
RESULTS

PCR Using Different Blood Components
In a preliminary study, we performed PCR on whole blood and plasma samples from 21 patients with IC and 27 controls. (Table 3) , 5 with mucosal candidiasis (esophagitis, n 5 3; oropharyngeal, n 5 1; vaginitis, n 5 1), and 20 with no known Candida colonization. The performance of PCR and BDG is summarized in Table 4 . The sensitivity of the tests was not affected by antifungal therapy (Table 5 ). Using the standard BDG cutoff for positivity ($80 pmol/mL; indeterminate result 5 negative), both BDG and PCR were positive for 42% (23 of 55) of patients with IC and negative for 5% (3 of 55) ( Table 6 ). Details of the patients with false negative results by both assays appear in Table 7 . Polymerase chain reaction was positive and BDG negative for 38% (21 of 55) of patients, and BDG was positive and PCR negative for 15% (8 of 55). The sensitivity of either a positive PCR or BDG for diagnosing IC was 95% (52 of 55), and specificity was 56% (41 of 73).
Comparison of PCR and BDG With Blood Cultures
Among the 24 patients with deep-seated candidiasis in whom blood cultures were performed concurrently, both PCR (88% [21 of 24] ) and BDG (62% [15 of 24] ) were more sensitive than blood cultures (17% [4 of 24]; P 5 .0005 and P 5 .003, respectively) ( Figure 1 ). If indeterminate BDG results were considered positive, sensitivity was 67% (16 of 24; P 5 .002 vs blood culture). At either BDG cutoff, sensitivity did not differ from PCR (P 5 .15 and .23, respectively).
Among the 42 patients with IC in whom blood cultures were obtained, the sensitivity of either a positive PCR or positive blood culture was 98% (41 of 42). The sensitivities of either a positive BDG or positive blood culture were 79% (33 of 42; indeterminate 5 negative) and 81% (34 of 42; indeterminate 5 positive).
Identification of Candida Species by PCR and Culture
In 82% (36 of 44) of patients with a positive PCR result, PCR and culture identified $1 Candida species in common (Table 8) . There was complete agreement in speciation between PCR and culture for 45% (20 of 44) of patients.
DISCUSSION
This study was designed as a head-to-head comparison of PCR and BDG in diagnosing IC. We prospectively enrolled and collected blood from hospitalized patients in 3 well-defined Candida PCR assays were tested against 7 target species, 12 nontargeted Candida species, 27 other fungi, and 28 bacteria. Unless noted in parentheses, the number of isolates tested was 1 per organism. Target Candida species were detected by the indicated assays in brackets.
Abbreviations: CA, Candida albicans; CG, Candida glabrata; CK, Candida krusei; CP, Candida parapsilosis complex; CT, Candida tropicalis.
groups: candidemia, deep-seated candidiasis, and controls without IC. To maximize the rigor of the study, the latter group was overwhelmingly composed of patients who were colonized with Candida species or diagnosed with mucosal candidiasis. Our data yielded 2 particularly important findings. First, PCR was superior to BDG for diagnosing deep-seated candidiasis (sensitivity: 89% vs 53% or 66%, depending upon the BDG interpretive cutoff; P 5 .004 and .04, respectively). Polymerase chain reaction also was significantly more sensitive for diagnosing all cases of IC at the standard cutoff for BDG positivity (80% vs 56%; P 5 .03). Second, both PCR and BDG were markedly superior to blood cultures among patients with deep-seated candidiasis (88% and 62% vs 17%; P 5 .0005 and P 5 .003, respectively). Taken together, the results indicate that PCR may join BDG as a valuable adjunctive tool for diagnosing IC. Moreover, these assays are likely to identify a significant percentage of those patients with IC who are missed by blood culture, the current gold standard diagnostic test. The limitations of blood cultures for diagnosing IC are well recognized [1] [2] [3] . Indeed, blood cultures are positive in ,50% of patients with hepatosplenic candidiasis or autopsyproven IC [1, 3] . The use of antifungals for prophylaxis or empiric therapy may further reduce the sensitivity of blood cultures [10] . Although advances in microbiology techniques have improved the recovery of Candida species, the low magnitude and short duration of candidemia suggest that the sensitivity of blood cultures will remain inadequate [11] [12] [13] [14] . Our results are consistent with previous reports that PCR and BDG were more sensitive than blood culture for diagnosing IC [4, [15] [16] [17] . There are several potential reasons for the heightened sensitivities of these assays. In the case of PCR, the amplification of a high-copy DNA target facilitates detection of lower inocula of Candida in the blood. In fact, the lower limit of detection for the assay used in this study is 80 Candida copies/mL of serum or plasma, which corresponds to approximately 0.4 colony-forming units/mL (,1 genome). At the same time, PCR amplifies DNA from both dead and viable Candida cells as well as freely circulating DNA [13, 18] . Likewise, BDG detection is not dependent on viable organisms [5, 19] . The reasons that PCR was more sensitive than BDG in diagnosing deep-seated candidiasis are not apparent, which reflects our limited understanding of the bloodstream kinetics of Candida DNA and BDG. In animal models of IC, serum PCR remained positive after sterilization of blood, suggesting that free DNA is eliminated slowly [13, 18] .
It is notable that the sensitivity of PCR for diagnosing candidemia was significantly lower than deep-seated candidiasis (P 5 .009). Similar results were reported previously [4] . A potential explanation for our findings is that patients were enrolled at the time of positive cultures. As such, transient or catheter-associated candidemias already may have resolved spontaneously or as a result of catheter removal. During deep-seated candidiasis, Candida DNA may be continuously (9) Abdominal surgery within 1 month of enrollment 24% (13) 8% (6) Extra-abdominal surgery within 1 month of enrollment 5% (4) 7% (5) None of the patients had hematologic malignancy or neutropenia at the time of invasive candidiasis. Fifty-four percent (30 of 55) of patients with invasive candidiasis (IC) were receiving an antifungal agent at the time blood was collected (fluconazole, n 5 20; echinocandin, n 5 9; voriconazole, n 5 1). The median time from the start of antifungal therapy to sample collection was 5 days (range, 1-39). a One patient with IC had both liver disease and small bowel obstruction. released into the bloodstream, which could also explain the persistence of serum PCR positivity after the clearance of blood cultures in animal models of IC [13, 18] . Our results call to mind previous studies in which mannoproteinemia was detected in only 7% of patients with transient or catheterassociated candidemia compared with 76% with persistent candidemia or IC [20, 21] . On the whole, the data highlight that PCR and BDG will be most useful as diagnostic adjuncts to blood cultures rather than as replacements. Indeed, the sensitivity of blood culture combined with PCR or BDG among patients with IC was 98% and 79%-81%, respectively, which was better than any of the tests alone. Since positive blood cultures by definition are diagnostic of IC, they improve the sensitivity of nonculture-based assays without impacting their specificity. Blood cultures also permit antifungal susceptibility testing. The combination of PCR and BDG was less useful. Depending on the BDG cutoff, the sensitivity of the combined tests was 95%-96%, but specificity was only 47%-56%. It is difficult to compare our results with previous reports because of differences in study design, definitions of IC, patient populations and negative controls, and interpretive criteria [7, 16] . Technical issues also differ, including the fraction of specimens subjected to DNA extraction, choice of primers and probes, amplification parameters in PCR studies, and the particular detection assay for BDG [6, 22] . In this regard, the use of a validated and publically available PCR assay in this study is a major advance, which should facilitate comparisons between centers and populations in the future. Along these lines, it is notable that we corroborated earlier observations that the sensitivity of PCR on plasma or sera was superior to whole blood [13, 18, 23, 24] , which likely reflects an absence of PCR inhibitors, less cumbersome DNA extraction methods, and the more ready detection of cell-free fungal DNA within these compartments. On balance, the performance of PCR was in keeping with other reports, in which sensitivities ranged from 73% to 95% [7, 16] . In studies of BDG monitoring for early diagnosis of IC, sensitivity and specificity varied widely (64%-100% and 71%-98%, respectively) [4] [5] [6] 22] . The lower sensitivity of BDG in our experience may reflect the large percentage of patients with deep-seated candidiasis.
Overall, PCR and BDG demonstrated adequate specificity (70% and 63%-73%, respectively, depending on BDG cutoff). In fact, the specificity of PCR and BDG in this study is likely to be lower than in most clinical practices, due to the composition Table 6 . False-positive BDG results have also been attributed to Candida colonization, systemic bacterial infections, antibiotics, cellulose membranes used during hemodialysis, and cotton gauze and sponges [25] . Of note, the specificity of BDG at the lower cutoff for positivity ($60 pmol/mL) was only 50% among colonized patients, which may limit the utility of this cutoff. A possible advantage of PCR over BDG is the ability for speciation. The PCR assay used in this study was designed to distinguish fluconazole-susceptible species (C. albicans and C. tropicalis) from intrinsically or potentially resistant species (C. krusei and C. glabrata) and C. parapsilosis, which often demonstrates reduced echinocandin susceptibility. Overall, speciation by culture and species-specific PCR was in agreement in 82% of patients. There are several potential explanations for disagreements in the remaining cases. First, PCR speciation may be incorrect. In most instances, we do not think this was the case because there was no misspeciation of Candida isolates in preliminary experiments (Table 1) . Second, the speciation in our clinical lab may be incorrect. Indeed, studies of clinical labs have indicated that Candida species were misidentified in 8%-15% of specimens [26] [27] [28] [29] . Third, the clinical lab may have missed cases caused by multiple species. We found that 2 species were identified in 5% of blood cultures, which is consistent with rates of at least 4% reported in the literature [30, 31] . At the same time, PCR identified at least 2 species in 36% of samples, suggesting that the clinical laboratory may not have isolated unique colonies for speciation. Fourth, time lags between culture and PCR sample collection may have contributed to disagreements, because it is possible that a particular infecting Candida species was no longer in the circulation. Finally, many of the cultures were performed on deep-seated 8% (2) 0% (0) 8% (2) 4% (1) 38% (9) 42% ( samples, whereas PCR was performed on plasma or sera. Different species may have been present at different sites. If culture and PCR give discordant results in clinical practice, the wisest course is to treat as if the more resistant species is present. In this regard, it is notable that the most common disagreement was blood culture identifying C. albicans and PCR identifying C. glabrata or C. krusei.
It is important to acknowledge limitations of our study. First, PCR and BDG testing was performed in batches on frozen samples. As such, we cannot exclude that some negative results may have stemmed from sample instability. Second, antifungal use did not impact the performance of PCR or BDG, but the majority of patients received an azole. Thus, we could not assess the potential impact of BDG synthesis inhibition by the echinocandins on the performance of the BDG assay. Third, the number of controls with mucosal candidiasis was small; therefore, the specificity of PCR and BDG in this population needs further study. Fourth, blood for BDG and PCR was obtained after the diagnosis of IC was confirmed by culture and at only 1 time point, which precluded the evaluation of the tests for disease screening. Future studies should include serially collected blood samples from patients at high risk for IC.
In conclusion, we demonstrated that Candida PCR and, to a lesser extent, BDG testing significantly enhanced the ability of blood cultures to diagnose IC. As for all diagnostic tests, best results will be obtained if PCR and BDG are limited to situations in which there is a reasonable likelihood of IC. Employed judiciously, these assays have the potential to identify a large population of patients with deep-seated candidiasis missed by blood cultures. If our findings are validated in other studies, the results will have a major impact on the treatment of IC, our understanding of its pathogenesis, and the design of clinical trials. Follow-up studies to evaluate the impact of Candida PCR and BDG on the diagnosis, treatment, and outcome of IC are indicated.
Notes
